

**APPLICATION FOR STEM CELL OVERSIGHT COMMITTEE REVIEW**

For new applications and amendments to applications previously reviewed by SCOC.

A. General Information

Nominated Principal Applicant:

Mailing address of Principal Applicant:

E-mail address of Principal Applicant:

All Other Applicants:

Funding Agency:

Application Number:

Title:

Competition Date:

Application status:Peer reviewed: Yes No Approved for funding: Yes No If yes, date of approval:

(dd/mm/yyyy)

B. Describe:

i) Which human pluripotent stem cell lines will be used?:

ii) **The need for human pluripotent stem cells:** explain why human pluripotent stem cells are required for the research proposed. For amendments to applications previously approved by SCOC, please indicate why the additional cell lines are required for the research.iii) **The potential benefits for the health of Canadians:**

C. Appendices:

- i) One copy of the original application for funding, including CV, or if this is an amendment to an application previously approved by SCOC, a copy of the original SCOC application**
- ii) If this application is being submitted for Trainee funding, is this project wholly subsidiary to a SCOC-approved project?**
Yes : Please append a signed attestation from the supervisor that the student proposal is wholly subsidiary to a SCOC-approved project. This should include the title of the approved project, the name of the project lead, the date submitted to SCOC, and the source of funds for the approved project.
No : Please append a protocol for the research proposed.
 This is not an application for Trainee funding
- iii) Copies of consent and information forms used**
Copies of
 - a) unsigned research consent (see section 8.3.2 of the Guidelines); and/or
 - b) unsigned embryo donor or research subject consent; and
 - c) information formsare required when:
 - Requesting the use of human pluripotent stem cell lines not previously approved by SCOC that have been derived from embryos, fetal tissue, or amniotic fluid; or
 - The research involves deriving new human pluripotent stem cell lines from embryos, fetal tissue or amniotic fluid; or
 - The research involves grafting human pluripotent stem cell lines into human subjects

- iv) Copies of any contracts relevant to this application, and any relevant budgetary information. Please see Section 8.4.2 of the Guidelines:**
Copies of contracts between researchers, institutions and industry sponsors and any relevant budgetary information must be provided to the Stem Cell Oversight Committee and the local REB, to examine and evaluate any potential or actual conflict of interest and to ensure the right to publish freely after a modest interval.
Should any potential conflicts of interest arise following approval of an application, the Stem Cell Oversight Committee should be advised.
Please list all contracts that are appended:

- There are no relevant contracts**

- v) Description of any financial interest you may have in the outcome of the research described in this application. See Section 8.4.1 of the Guidelines:**
When researchers or their institutions acquire financial interests in the outcome of the stem cell research, including, but not limited to, income from commercial firms supporting their research, stock holdings in corporations supporting their research, or patents in products produced through their research, they must disclose this information to the Stem Cell Oversight Committee, the REB and prospective research participants. In some instances, disclosure may not be a sufficient response to concerns about actual, perceived or potential conflicts of interest and researchers and/or their institutions may be asked by SCOC to remedy any possible distortion of proper procedures attributable to such conflicts
Should any potential conflicts of interest arise following approval of an application, the Stem Cell Oversight Committee should be advised.
- I have no financial interest in the outcome of the research described in this application**

D. Certification

- i) Certification that any human embryonic stem cell lines generated under the auspices of federal funding agencies (CIHR, NSERC, SSHRC) will be listed with the registry and made available to other researchers, subject to reasonable cost-recovery charges. See Section 6.0 of the Guidelines:**
All human embryonic stem cell lines generated using CIHR funds will be listed with the registry and made available by the researcher to other Canadian academic researchers, subject to reasonable cost-recovery charges. Participation in this registry will be a prerequisite for obtaining CIHR funding for human pluripotent stem cell research.
Yes
No
Not applicable

- ii) Confirmation that an amended application will be submitted to SCOC for review and approval if any changes in direction of the research involving human pluripotent stem cells are contemplated, before such work commences (e.g. use of any human pluripotent stem cell lines other than those previously approved by SCOC). This includes when a Trainee submits a proposal to conduct research that differs from the original proposal.**
Yes
No

- iii) Confirmation that SCOC will be provided with written notification should the use of additional SCOC-approved stem cell lines not described in the original research application be contemplated (this notification would include details of the original application (title, PI, date submitted to SCOC) and indicate which cell lines would be used).**
Yes
No

iv) Will any non-human animals be engrafted with human embryonic stem cells or cells derived from human embryonic stem cells in this project?

Yes (see below)

No

If yes, confirmation that any non-human animals engrafted with human embryonic stem cells or cells derived from human embryonic stem cells in the course of this research will not be used for reproductive purposes.

Yes

No

v) Confirmation that you understand your research institution's conflict of interest policy and that you will comply with that policy

Yes

No

I certify that all information provided above is correct to the best of my knowledge.

Signed (Nominated Principal Investigator)

Date

Signed (Other Applicant)

Date

Signed (Other Applicant)

Date

Please send completed form to:

Stem Cell Oversight Committee
Canadian Institutes of Health Research
160 Elgin St., 9th Floor
Address Locator 4809A
Ottawa, Ontario K1A 0W9

Notes:

- 1) Only applications that have been approved for funding should be submitted for SCOC review.
- 2) Researchers should consult the stem cell research guidelines ("the Guidelines") and Frequently Asked Questions posted on the CIHR website (<http://www.cihr-irsc.gc.ca/e/15255.html>) to determine whether or not the research requires review by the Stem Cell Oversight Committee (SCOC). Any questions can be directed to stemcell@cihr-irsc.gc.ca.
- 3) Recommendations from SCOC are sent to CIHR's Governing Council for final decision.
- 4) Additional information may be requested from the researcher by if SCOC has concerns that are not addressed in the documentation provided.